



Malawi COVID-19 Emergency Response and Health Systems Preparedness Project (P173806)

AFRICA EAST | Malawi | Health, Nutrition & Population Global Practice |
IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 4 | ARCHIVED on 29-Nov-2021 | ISR48722 |

Implementing Agencies: Ministry of Health, Republic of Malawi

Key Dates**Key Project Dates**

Bank Approval Date: 14-Apr-2020

Effectiveness Date: 30-Apr-2020

Planned Mid Term Review Date: --

Actual Mid-Term Review Date:

Original Closing Date: 31-May-2022

Revised Closing Date: 31-Dec-2023

Project Development Objectives

Project Development Objective (from Project Appraisal Document)

To prevent, detect and respond to the threat posed by COVID-19 in Malawi and strengthen national systems for public health preparedness.

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

Components Table

Name

Emergency COVID-19 Response:(Cost \$34.10 M)

Supporting National and Sub-national, Prevention and Preparedness:(Cost \$0.95 M)

Implementation Management and Monitoring and Evaluation:(Cost \$1.95 M)

Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Moderately Satisfactory	<input type="checkbox"/> Moderately Satisfactory
Overall Risk Rating	<input type="checkbox"/> High	<input type="checkbox"/> Substantial

Implementation Status and Key Decisions

The Malawi COVID-19 Emergency Response Project aims to support the Government of Malawi's (GoM) effort to respond to COVID-19. The project is aligned to the GoM COVID-19 Preparedness and Response Plan and complements support from other development partners. The original project became effective on April 30, 2020. In June 15, 2021, Additional Financing (AF) in the amount of US\$30 million was approved and was declared effective on August 23, 2021. The AF brings the total financing for the project to US\$37 million, of which US\$5.45 million has been disbursed (14.7% of the total grant) as of October 15, 2021. The AF is primarily to support the GoM's efforts in procurement and deployment of COVID-19 vaccines as well as selected aspects of health systems strengthening. The GoM has already submitted an order for the procurement of about 1.86 million Johnson and Johnson (J&J) COVID-19 vaccines through African Vaccine Acquisition Trust (AVAT). With the AF, the project period has been extended to December 31, 2023. In addition, the implementation and institutional arrangements have been adjusted to account for



the expanded scope of the project. The project has procured key supplies and equipment needed to contribute to the implementation of the GoM's COVID-19 response and trained various health worker cadres on COVID-19 case detection, confirmation, management and contact tracing.

MPA Program Development Objective

The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

Multiphase Programmatic Approach (MPA) Status

As of November 15, 2021, 87 MPA-projects had been approved with a total commitment of US\$4.2 billion. One operation (Guatemala) was cancelled in mid-September, at the request of the Government. Therefore, there are 86 MPA active operations. The pace of disbursements during the past month has increased. Fifty-seven (57) country projects or 66% of projects approved have reached 70-100% disbursement (reasons for >100% disbursements relate to fluctuations between the Euro and the SDR against the US\$). The projects are benefitting around 3.7 billion people or 50% of the global population. Of the 86 active projects: (i) 33 are in Africa – 12 in AFE and 21 in AFW; (ii) 12 in East Asia; (iii) 14 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 7 in Middle East and North Africa; and (vi) 9 in South Asia. Eighty-five (85) or 99% of projects approved are disbursing. **Total disbursements as of November 15, 2021, amounted to US\$3.25 billion or 77% of overall commitments.** Streamlined procedures, delegated approvals coupled with flexible project design and intensified efforts across the Bank have contributed to the progress. **Several projects have/are being restructured to include vaccine-related procurement.** Implementation is being guided by Bank teams working in parallel with other health related projects, including Additional Financing operations supporting vaccine procurement and deployment efforts. Implementation continues to face challenges as several countries are still under different levels of lockdown or mobility restrictions, and counterparts and Bank teams are operating from home or partially from home. Also, countries are dealing with new waves of infections as the Delta variant spreads rapidly among populations. Many Bank teams continue to conduct implementation support missions virtually, which is challenging for both Bank teams and counterparts. This “virtual” world poses connectivity challenges as internet is not reliable in many countries, especially IDA countries. Notwithstanding the challenges, the MPA is on track to achieve its PrDO, which is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness. The significant level of disbursements in just over 19 months attests to the strong implementation of the Bank' response thanks to the commitment of counterparts supported by Bank country teams.

The Additional Financing (MPA AF-V) to the COVID-19 Strategic Preparedness and Response Program utilizing the Multiphase Programmatic Approach (“Global COVID-19 MPA”) was approved by the Board on October 13, 2021. The AF-V is significantly expanding Bank support to client countries for COVID-19 vaccination, with the aim to support vaccination of 1 billion people globally. The AF-V was approved with an envelope of US\$12 billion (\$6 billion from IDA and \$6 billion from IBRD) in financing. This financing is critical to expand affordable and equitable financing for vaccine purchase and deployment. The AF-V is expected to enable vaccination for up to 750 million people, with potential surge capacity for an additional 250 million people in the poorest countries (depending on the delivered price of approved vaccines) while scaling support to strengthen immunization delivery, with design flexibility at the country level. The AF-V is a scale-up of planned vaccination activities already anticipated and supported under the Global COVID-19 MPA and a key contribution to the WBG's overall COVID-19 response.

As of November 15, 2021, the Bank has approved 65 operations to support vaccine procurement and rollout in 62 countries amounting to \$5.8 billion. The 65 AF-V operations approved, include 4 operations that involved restructuring of parent projects (North Macedonia, Philippines and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project. Of the 65 approved operations: (i) 35 are in Africa – 16 in AFE



and 19 in AFW; (ii) 7 in East Asia; (iii) 7 in Europe and Central Asia; (iv) 5 in Latin America and the Caribbean; (v) 5 in Middle East and North Africa; and (vi) 6 in South Asia. Thirty three (33) projects are disbursing. **Total disbursements as of November 15, 2021, under these projects amount to US\$1,046 million or 18% of overall commitments.** As with the MPA operations, streamlined procedures, delegated approval, coupled with flexible project design and intensified efforts across the Bank have contributed to the rapid design and processing of the operations. Sixty-three (63) loan/financing agreements have already been signed. Also, fifty-three (53) loan/financing agreements have become effective; several others are expected to become effective in the coming days/weeks. Implementation of the AF-V operations, as with MPA operations is facing challenges as many countries are still under different levels of lockdown or mobility restrictions and counterparts and Bank teams are operating from home.

Risks

Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	Substantial	Substantial	Substantial
Macroeconomic	Substantial	Substantial	Substantial
Sector Strategies and Policies	Moderate	Moderate	Moderate
Technical Design of Project or Program	Moderate	High	Substantial
Institutional Capacity for Implementation and Sustainability	Substantial	High	Substantial
Fiduciary	Substantial	Substantial	Substantial
Environment and Social	Substantial	Substantial	Substantial
Stakeholders	Substantial	Substantial	Substantial
Other	--	--	--
Overall	Substantial	High	Substantial

Results

PDO Indicators by Objectives / Outcomes

To strengthen national systems for public health preparedness				
▶ Percentage of designated laboratories with staff trained to conduct COVID-19 diagnosis. (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	67.50	110.00	80.00
Date	15-Apr-2020	15-Apr-2021	20-Oct-2021	31-Dec-2023
Comments:	The allocated budget was able to cover more trainings than initially anticipated			



To prevent, detect and respond to the threat posed by COVID-19				
▶ Percentage of suspected cases of COVID-19 cases reported and investigated based on national guidelines (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	27.00	38.00	80.00
Date	15-Apr-2020	15-Apr-2021	20-Oct-2021	31-Dec-2023
▶ Percentage of designated health facilities ready to treat COVID-19 (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	80.00
Date	15-Apr-2020	15-Apr-2021	20-Oct-2021	31-Dec-2023
▶ Percentage of targeted population fully vaccinated based on the targets defined in national plan, disaggregated by gender (Percentage) (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	28.00
Date	01-Jun-2021	01-Jun-2021	20-Oct-2021	31-Dec-2023
Comments:	Since AF activities have not started and no project resources to date have gone towards COVID-19 vaccine purchase and deployment support activities, all related indicators remain at baseline levels			
□ Percentage of females fully vaccinated (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	50.00
Date	01-Jun-2021	01-Jun-2021	20-Oct-2021	31-Dec-2023

Intermediate Results Indicators by Components

Emergency COVID-19 Response				
▶ Number of health staff trained in infection prevention and control per MOH-approved protocols (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	948.00	948.00	870.00
Date	15-Apr-2020	15-Apr-2021	20-Oct-2021	31-Dec-2023
Comments:	Activity completed. The allocated budget was able to cover more trainings than initially anticipated			



► Oxygen plant installed and functional (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	No	No	Yes
Date	01-Jun-2021	01-Jun-2021	20-Oct-2021	31-Dec-2023
Comments:	Since AF activities have not started and no project resources to date have gone towards COVID-19 vaccine purchase and deployment support activities, all related indicators remain at baseline levels			
► Number of health surveillance assistants (HSAs) oriented in contact tracing, by gender. (Number) (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	7.00	4,049.00	4,500.00
Date	15-Apr-2020	15-Apr-2021	20-Oct-2021	31-Dec-2023
Comments:	In the parent project this indicator was "Number of teams trained in contact tracing". This indicator was now revised to be "Number of HSAs oriented in contact tracing". The Previous value for the revised indicator is 2894 (as indicated in comment section of the last ISR). The current value is 4,049.			
☐ Number of female health surveillance assistants (HSAs) oriented in contact tracing (Number) (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	1,791.00	2,025.00
Date	01-Jun-2021	01-Jun-2021	20-Oct-2021	31-Dec-2023
► Healthcare workers training materials were assessed to identify the extent to which Gender-Based Violence (GBV) is addressed (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	No	No	Yes
Date	11-Jun-2021	11-Jun-2021	20-Oct-2021	31-Dec-2023
Comments:	Since AF activities have not started and no project resources to date have gone towards COVID-19 vaccine purchase and deployment support activities, all related indicators remain at baseline levels			
► Number of healthcare professionals (HCPs) and district investigation officers trained on detection and reporting, or investigation of AEFIs, by gender (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	1,475.00
Date	11-Jun-2021	11-Jun-2021	20-Oct-2021	31-Dec-2023
Comments:	Since AF activities have not started and no project resources to date have gone towards COVID-19 vaccine purchase and deployment support activities, all related indicators remain at baseline levels			



<input type="checkbox"/> Number of female healthcare professionals (HCPs) and district investigation officers trained on detection and reporting, or investigation of AEFIs. (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	516.00
Date	11-Jun-2021	11-Jun-2021	20-Oct-2021	31-Dec-2023
► Percentage of targeted population who received at least one dose of a COVID-19 vaccine, by gender (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	28.00
Date	11-Jun-2021	11-Jun-2021	20-Oct-2021	31-Dec-2023
Comments:	Since AF activities have not started and no project resources to date have gone towards COVID-19 vaccine purchase and deployment support activities, all related indicators remain at baseline levels			
<input type="checkbox"/> Percentage of females who received at least one dose of a COVID-19 vaccine (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	50.00
Date	11-Oct-2021	11-Jun-2021	20-Oct-2021	31-Dec-2023
► CSO representatives are active members of the National Task Force (NTF) responsible for monitoring and guiding the COVID-19 vaccine rollout. (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	No	No	Yes
Date	11-Jun-2021	11-Jun-2021	20-Oct-2021	31-Dec-2023
Comments:	Since AF activities have not started and no project resources to date have gone towards COVID-19 vaccine purchase and deployment support activities, all related indicators remain at baseline levels			

Supporting National and Sub-national, Prevention and Preparedness

► Number of health staff trained in emerging infectious diseases (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	250.00	180.00
Date	15-Apr-2020	15-Apr-2021	20-Oct-2021	31-May-2022



Implementation Management and Monitoring and Evaluation				
► Percentage of grievances addressed within 4 weeks of initial complaint being recorded (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	80.00
Date	15-Apr-2020	15-Apr-2021	20-Oct-2021	31-May-2022
Comments:	No grievances have been reported thus far.			
► M&E system established to monitor COVID-19 preparedness and response plan (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	No	No	Yes
Date	15-Apr-2020	15-Apr-2021	20-Oct-2021	31-Dec-2023
Comments:	Awaiting to populate the RF for the National COVID-19 Preparedness and Response Plan			

Performance-Based Conditions

Data on Financial Performance


Disbursements (by loan)

Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
P173806	IDA-D6200	Effective	USD	7.00	7.00	0.00	6.23	1.11	85%
P173806	IDA-D8870	Effective	USD	30.00	30.00	0.00	0.00	29.62	0%

Key Dates (by loan)

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P173806	IDA-D6200	Effective	14-Apr-2020	17-Apr-2020	30-Apr-2020	31-May-2022	31-Dec-2023
P173806	IDA-D8870	Effective	15-Jun-2021	02-Jul-2021	23-Aug-2021	31-Dec-2023	31-Dec-2023

Cumulative Disbursements



PBC Disbursement

PBC ID	PBC Type	Description	Coc	PBC Amount	Achievement Status	Disbursed amount in Coc	Disbursement % for PBC
--------	----------	-------------	-----	------------	--------------------	-------------------------	------------------------

Restructuring History

There has been no restructuring to date.

Related Project(s)

P176402-Additional Financing for Malawi COVID-19 Emergency Response and Health Systems Preparedness Project ,P178095-Additional Financing for Malawi COVID-19 Emergency Response and Health Systems Preparedness Project